Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $5.88 million for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +56.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $137.1 thousand | Q3 2017: $40.4 thousand | Q1 2018: $54.0 thousand | Q2 2018: $150.0 thousand | Q3 2018: $4.82 million | Q1 2019: $11.39 million | Q2 2019: $10.25 million | Q3 2019: $8.53 million | Q4 2019: $6.78 million | Q1 2020: $4.95 million | Q2 2020: $8.62 million | Q3 2020: $7.37 million | Q1 2021: $5.64 million | Q2 2021: $5.21 million | Q3 2021: $7.18 million | Q1 2022: $12.69 million | Q2 2022: $9.16 million | Q3 2022: $5.75 million | Q1 2023: $2.31 million | Q2 2023: $1.22 million | Q3 2023: $315.9 thousand | Q1 2024: $5.03 million | Q2 2024: $3.29 million | Q3 2024: $5.20 million | Q1 2025: $2.37 million | Q2 2025: $5.91 million | Q3 2025: $4.61 million.
- Over the full 10 years of available data (2016 to 2025), ADIAL PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 6,583.7%.
- Historical annual values: Fiscal year 2025: $5.88 million | Fiscal year 2024: $3.75 million | Fiscal year 2023: $2.83 million | Fiscal year 2022: $4.00 million | Fiscal year 2021: $6.06 million | Fiscal year 2020: $4.40 million | Fiscal year 2019: $6.78 million | Fiscal year 2018: $3.87 million | Fiscal year 2017: $18.2 thousand | Fiscal year 2016: $88.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: